ReviewResearch (Washington, D.C.)2025
High Suitcordance for Panvascular Full-Watershed Organs: A New Interventional Perspective.
Review in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From intravascular imaging to adaptive vascular care: intelligent photonics and digital twins in panvascular disease.Light, science & applications · 2026Review
- The multidimensional roles and mechanisms of exercise intervention in pediatric oncology.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Panvascular medicine underscores the integration of vascular networks across organs such as the heart, brain, kidneys, and limbs into a unified system. In this system, metabolic aberrations, endothelial dysfunction, and hemodynamic disturbances in one organ can drive synergistic pathologies elsewhere. However, current interventional device development has largely overlooked richly vascularized, high-perfusion organs like the liver and kidneys. Furthermore, the pervasive challenge of "low suitcordance"-a term we introduce to describe suboptimal device performance over its entire life cycle-confronting interventional devices for panvascular full-watershed organs remains unresolved. (Here, the term "full-watershed" metaphorically denotes organs that, like geographical watersheds, receive marked perfusion from the systemic circulation, emphasizing their collective role in panvascular health.) This article introduces "suitcordance" (short-term suitability and long-term concordance) as a novel framework for evaluating device performance that transcends traditional metrics like biocompatibility. We propose that interdisciplinary innovation, fusing materials science, biomechanics, mechanobiology, and artificial intelligence can address this gap. The Xinsorb bioresorbable scaffold illustrates a path toward "high suitcordance" devices, offering a paradigmatic reference for interventions in cerebral, peripheral, hepatic, and renal vasculatures. This approach provides a new paradigm for advancing interventional devices from isolated vascular repair to the synergistic management of multivascular bed lesions and the restoration of systemic functional equilibria.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.